博雅生物拟出让博雅欣和80%股权

Core Viewpoint - The company plans to divest 80% of its stake in Jiangxi Boya Xinhao Pharmaceutical Co., Ltd. to focus on its core blood products business and optimize resource allocation, enhancing capital return levels [1][3]. Group 1: Transaction Details - The transaction will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with an initial listing price of 213 million yuan, subject to the valuation approved by the state-owned assets supervision authority [1]. - After the completion of the share transfer, the company will hold 10.69% of Boya Xinhao, and it will no longer be included in the company's consolidated financial statements [2]. Group 2: Business Performance - In 2024, the company reported total revenue of 1.735 billion yuan, a decrease of 34.58% year-on-year, while net profit attributable to shareholders was 397 million yuan, an increase of 67.18% compared to the previous year [2]. - The company achieved a plasma collection of 630.6 tons in 2024, representing a year-on-year growth of 10.4%, with the main entity, China Resources Boya, collecting 522.04 tons, up 11.7%, exceeding the industry average growth rate [2]. Group 3: Strategic Implications - The divestiture is expected to optimize the company's business structure, focus on core development, enhance sustainable internal growth, facilitate capital flow, and activate existing production capacity, ultimately promoting high-quality development [3].